Esperion Therapeutics Stock Price, News & Analysis (NASDAQ:ESPR)

$78.90 +0.96 (+1.23 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$78.90
Today's Range$77.11 - $79.68
52-Week Range$20.39 - $82.18
Volume282,252 shs
Average Volume640,460 shs
Market Capitalization$2.07 billion
P/E Ratio-11.24
Dividend YieldN/A
Beta2.64

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ESPR
CUSIPN/A
Phone+1-734-8873903

Debt

Debt-to-Equity RatioN/A
Current Ratio6.15%
Quick Ratio5.91%

Price-To-Earnings

Trailing P/E Ratio-11.2393162393162
Forward P/E Ratio-12.35
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.23 per share
Price / Book8.55

Profitability

Trailing EPS($7.02)
Net Income$-74,970,000.00
Net MarginsN/A
Return on Equity-76.84%
Return on Assets-67.42%

Miscellaneous

Employees44
Outstanding Shares26,500,000

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) released its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.36. During the same quarter last year, the business posted ($1.29) EPS. View Esperion Therapeutics' Earnings History.

When will Esperion Therapeutics make its next earnings announcement?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Esperion Therapeutics.

Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2018?

12 brokerages have issued 1 year price targets for Esperion Therapeutics' stock. Their forecasts range from $45.00 to $105.00. On average, they anticipate Esperion Therapeutics' stock price to reach $78.67 in the next year. View Analyst Ratings for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

  • 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
  • 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
  • 3. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:

  • Timothy M. Mayleben, President, Chief Executive Officer, Director (Age 56)
  • Richard B. Bartram, Chief Financial Officer and Principal Financial Officer (Age 36)
  • Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development (Age 64)
  • Nicole Vitullo MBA, Independent Lead Director (Age 59)
  • Jeffrey Berkowitz J.D., Director (Age 51)
  • Roger S. Newton Ph.D., FAHA, FACN, Director (Age 66)
  • Scott N. Braunstein M.D., Independent Director (Age 53)
  • Dov A. Goldstein M.D., Independent Director (Age 49)

Who owns Esperion Therapeutics stock?

Esperion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Meditor Group Ltd (8.87%), BlackRock Inc. (5.75%), DOMAIN PARTERS VII L P (4.20%), ALTA PARTNERS VIII, L.P. (2.70%), ALTA PARTNERS VIII, L.P. (2.70%) and Wasatch Advisors Inc. (2.65%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?

Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Discovery Capital Management LLC CT, Quantitative Investment Management LLC, Pinnacle Associates Ltd., Peregrine Capital Management LLC, Wasatch Advisors Inc., BlackRock Inc., Guggenheim Capital LLC and EAM Investors LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Dov A Md Goldstein and Nicole Vitullo. View Insider Buying and Selling for Esperion Therapeutics.

Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?

Esperion Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Hamilton Lane Advisors LLC, Ascend Capital LLC, Deutsche Bank AG, Amundi Pioneer Asset Management Inc., Meditor Group Ltd, UBS Asset Management Americas Inc. and Ontario Teachers Pension Plan Board. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy Esperion Therapeutics stock?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of Esperion Therapeutics stock can currently be purchased for approximately $78.90.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $2.07 billion. The biopharmaceutical company earns $-74,970,000.00 in net income (profit) each year or ($7.02) on an earnings per share basis. Esperion Therapeutics employs 44 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 Ranchero Dr Ste 150, ANN ARBOR, MI 48108-2837, United States. The biopharmaceutical company can be reached via phone at +1-734-8873903 or via email at [email protected]


MarketBeat Community Rating for Esperion Therapeutics (ESPR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  620
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Esperion Therapeutics (NASDAQ:ESPR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.642.50
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $78.67$76.33$59.09$49.05
Price Target Upside: 3.80% upside1.12% downside21.76% upside9.62% upside

Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History

Price Target History for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018JPMorgan Chase & Co.Reiterated RatingNeutral -> Neutral$55.00 -> $65.00HighView Rating Details
2/21/2018Needham & Company LLCReiterated RatingStrong-Buy -> Strong-Buy$81.00 -> $94.00LowView Rating Details
1/22/2018CitigroupDowngradeBuy -> Neutral$77.00 -> $96.00LowView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform -> Outperform$103.00LowView Rating Details
1/15/2018Stifel NicolausSet Price TargetPositive -> Buy$70.00 -> $105.00MediumView Rating Details
1/5/2018Bank of AmericaUpgradeNeutral -> Buy$76.00HighView Rating Details
12/6/2017Chardan CapitalBoost Price TargetNeutral$20.00 -> $75.00HighView Rating Details
11/10/2017Northland SecuritiesReiterated RatingBuy$72.00N/AView Rating Details
9/7/2017CowenInitiated CoverageOutperform$64.00LowView Rating Details
8/21/2017Jefferies GroupReiterated RatingBuy$85.00LowView Rating Details
8/9/2017Deutsche BankSet Price TargetBuy$48.00 -> $64.00HighView Rating Details
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00HighView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/31/2016BarclaysSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Esperion Therapeutics (NASDAQ:ESPR) Earnings History and Estimates Chart

Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ ESPR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($1.56)N/AView Earnings Details
2/20/2018Q4 2017($1.80)($1.44)ViewN/AView Earnings Details
11/7/2017Q3 2017($1.79)($1.86)ViewN/AView Earnings Details
8/8/2017Q2 2017($1.67)($1.92)ViewListenView Earnings Details
5/1/2017Q1 2017($1.44)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.68)($0.64)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.41)($0.34)ViewN/AView Earnings Details
8/12/2013Q2 2013($12.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Esperion Therapeutics (NASDAQ:ESPR) Earnings Estimates

2018 EPS Consensus Estimate: ($5.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.42)($1.42)($1.42)
Q2 20181($1.38)($1.38)($1.38)
Q3 20181($1.35)($1.35)($1.35)
Q4 20181($1.36)($1.36)($1.36)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Esperion Therapeutics (NASDAQ:ESPR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 87.67%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ ESPR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/25/2018Nicole VitulloDirectorSell11,674$71.79$838,076.463,177View SEC Filing  
12/6/2017Nicole VitulloDirectorSell9,326$53.85$502,205.102,472View SEC Filing  
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.0010,000View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.005,000View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00600View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.0041,614View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.0010,000View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.0034,614View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.0031,014View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Esperion Therapeutics (NASDAQ ESPR) News Headlines

Source:
DateHeadline
Esperion Targets $10 a Day for Heart Pill to Undercut RivalsEsperion Targets $10 a Day for Heart Pill to Undercut Rivals
finance.yahoo.com - February 23 at 5:33 PM
Q1 2018 EPS Estimates for Esperion Therapeutics Inc (ESPR) Lifted by AnalystQ1 2018 EPS Estimates for Esperion Therapeutics Inc (ESPR) Lifted by Analyst
www.americanbankingnews.com - February 23 at 9:59 AM
Stock Traders Buy Large Volume of Esperion Therapeutics Put Options (ESPR)Stock Traders Buy Large Volume of Esperion Therapeutics Put Options (ESPR)
www.americanbankingnews.com - February 23 at 8:26 AM
 Analysts Expect Esperion Therapeutics Inc (ESPR) to Post -$1.95 EPS Analysts Expect Esperion Therapeutics Inc (ESPR) to Post -$1.95 EPS
www.americanbankingnews.com - February 23 at 3:14 AM
Esperion Therapeutics Inc (ESPR) Forecasted to Earn FY2019 Earnings of ($5.35) Per ShareEsperion Therapeutics Inc (ESPR) Forecasted to Earn FY2019 Earnings of ($5.35) Per Share
www.americanbankingnews.com - February 22 at 3:26 PM
Esperion Therapeutics (ESPR) Given New $94.00 Price Target at Needham & Company LLCEsperion Therapeutics (ESPR) Given New $94.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - February 22 at 12:18 AM
Esperion Therapeutics (ESPR) Price Target Increased to $65.00 by Analysts at JPMorgan Chase & Co.Esperion Therapeutics (ESPR) Price Target Increased to $65.00 by Analysts at JPMorgan Chase & Co.
www.americanbankingnews.com - February 21 at 5:30 PM
UBS Group Analysts Give Esperion Therapeutics (ESPR) a $90.00 Price TargetUBS Group Analysts Give Esperion Therapeutics (ESPR) a $90.00 Price Target
www.americanbankingnews.com - February 21 at 5:30 PM
Esperion Therapeutics Inc (ESPR) Given Consensus Recommendation of "Buy" by AnalystsEsperion Therapeutics Inc (ESPR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 21 at 3:34 PM
Should You Be Concerned About Esperion Therapeutics Inc’s (NASDAQ:ESPR) Shareholders?Should You Be Concerned About Esperion Therapeutics Inc’s (NASDAQ:ESPR) Shareholders?
finance.yahoo.com - February 20 at 5:26 PM
Esperion Therapeutics (ESPR) Issues  Earnings ResultsEsperion Therapeutics (ESPR) Issues Earnings Results
www.americanbankingnews.com - February 20 at 10:56 AM
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial ResultsEsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 20 at 8:36 AM
3 Top Cholesterol Drug Stocks to Consider Buying Now3 Top Cholesterol Drug Stocks to Consider Buying Now
finance.yahoo.com - February 14 at 9:37 AM
Esperion Therapeutics (ESPR) to Release Earnings on TuesdayEsperion Therapeutics (ESPR) to Release Earnings on Tuesday
www.americanbankingnews.com - February 13 at 2:56 AM
Concert Pharmaceuticals (CNCE) versus Esperion Therapeutics (ESPR) Financial ComparisonConcert Pharmaceuticals (CNCE) versus Esperion Therapeutics (ESPR) Financial Comparison
www.americanbankingnews.com - February 9 at 5:10 AM
 Brokerages Anticipate Esperion Therapeutics Inc (ESPR) to Post -$1.80 EPS Brokerages Anticipate Esperion Therapeutics Inc (ESPR) to Post -$1.80 EPS
www.americanbankingnews.com - February 6 at 3:18 AM
Esperion Therapeutics Inc (ESPR) Receives Average Recommendation of "Buy" from BrokeragesEsperion Therapeutics Inc (ESPR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 3:22 PM
Esperion Therapeutics Inc (ESPR) Director Sells $838,076.46 in StockEsperion Therapeutics Inc (ESPR) Director Sells $838,076.46 in Stock
www.americanbankingnews.com - January 26 at 9:14 PM
Citi Downgrades Esperion As Hope Of Acquisition DwindlesCiti Downgrades Esperion As Hope Of Acquisition Dwindles
www.benzinga.com - January 22 at 11:33 AM
 Analysts Anticipate Esperion Therapeutics Inc (ESPR) to Post -$1.80 Earnings Per Share Analysts Anticipate Esperion Therapeutics Inc (ESPR) to Post -$1.80 Earnings Per Share
www.americanbankingnews.com - January 20 at 5:22 AM
Esperion Therapeutics (ESPR) Receives New Coverage from Analysts at Credit Suisse GroupEsperion Therapeutics (ESPR) Receives New Coverage from Analysts at Credit Suisse Group
www.americanbankingnews.com - January 17 at 5:24 PM
Esperion Therapeutics Target of Unusually High Options Trading (ESPR)Esperion Therapeutics Target of Unusually High Options Trading (ESPR)
www.americanbankingnews.com - January 15 at 4:40 AM
Esperion Therapeutics (ESPR) Upgraded to Strong-Buy at BidaskClubEsperion Therapeutics (ESPR) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - January 13 at 4:52 PM
Notable Friday Option Activity: BLK, ESPR, CZR - NasdaqNotable Friday Option Activity: BLK, ESPR, CZR - Nasdaq
www.nasdaq.com - January 12 at 5:01 PM
The 10 Best Stocks of 2017The 10 Best Stocks of 2017
finance.yahoo.com - January 8 at 9:44 AM
Esperion Therapeutics (ESPR) Upgraded to "Buy" by Bank of AmericaEsperion Therapeutics (ESPR) Upgraded to "Buy" by Bank of America
www.americanbankingnews.com - January 6 at 10:28 PM
Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017
finance.yahoo.com - January 6 at 5:07 PM
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare ConferenceEsperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:13 PM
Esperion Therapeutics Inc (ESPR) Given Average Recommendation of "Buy" by AnalystsEsperion Therapeutics Inc (ESPR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 2 at 3:40 PM
Analyzing Esperion Therapeutics (ESPR) and GenVec (GNVC)Analyzing Esperion Therapeutics (ESPR) and GenVec (GNVC)
www.americanbankingnews.com - January 2 at 7:30 AM
30 Big Biotech Events Coming in 201830 Big Biotech Events Coming in 2018
www.msn.com - December 30 at 9:29 AM
Commit To Purchase Esperion Therapeutics At $28, Earn 20.4% Using OptionsCommit To Purchase Esperion Therapeutics At $28, Earn 20.4% Using Options
www.nasdaq.com - December 22 at 9:47 AM
-$1.80 EPS Expected for Esperion Therapeutics, Inc. (ESPR) This Quarter-$1.80 EPS Expected for Esperion Therapeutics, Inc. (ESPR) This Quarter
www.americanbankingnews.com - December 17 at 5:32 PM
Esperion Therapeutics (ESPR) Upgraded at BidaskClubEsperion Therapeutics (ESPR) Upgraded at BidaskClub
www.americanbankingnews.com - December 16 at 10:16 AM
Esperion Therapeutics (ESPR) Appoints Jeffrey Berkowitz to Board - StreetInsider.comEsperion Therapeutics (ESPR) Appoints Jeffrey Berkowitz to Board - StreetInsider.com
www.streetinsider.com - December 15 at 5:45 PM
Esperion Therapeutics (ESPR) Upgraded to Strong-Buy by Needham & Company LLCEsperion Therapeutics (ESPR) Upgraded to Strong-Buy by Needham & Company LLC
www.americanbankingnews.com - December 14 at 8:32 PM
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of DirectorsEsperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
finance.yahoo.com - December 14 at 5:43 PM
Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy, Top Pick - StreetInsider.comNeedham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy, Top Pick - StreetInsider.com
www.streetinsider.com - December 14 at 9:47 AM
Head to Head Review: Esperion Therapeutics (ESPR) and Intellia Therapeutics (NTLA)Head to Head Review: Esperion Therapeutics (ESPR) and Intellia Therapeutics (NTLA)
www.americanbankingnews.com - December 12 at 7:34 PM
Esperion Therapeutics (ESPR) Rating Lowered to Hold at BidaskClubEsperion Therapeutics (ESPR) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 9 at 6:32 PM
Esperion Therapeutics, Inc. (ESPR) Director Sells $502,205.10 in StockEsperion Therapeutics, Inc. (ESPR) Director Sells $502,205.10 in Stock
www.americanbankingnews.com - December 8 at 5:50 PM
Esperion Therapeutics, Inc. (ESPR) Receives Average Rating of "Buy" from BrokeragesEsperion Therapeutics, Inc. (ESPR) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 5:42 PM
Chardan Capital Increases Esperion Therapeutics (ESPR) Price Target to $75.00Chardan Capital Increases Esperion Therapeutics (ESPR) Price Target to $75.00
www.americanbankingnews.com - December 6 at 10:38 PM
Esperion Therapeutics (ESPR) Hold Rating Reiterated at Chardan CapitalEsperion Therapeutics' (ESPR) Hold Rating Reiterated at Chardan Capital
www.americanbankingnews.com - December 5 at 8:48 PM
3 Stocks That Quadrupled3 Stocks That Quadrupled
finance.yahoo.com - December 4 at 9:37 AM
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - December 1 at 4:59 PM
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 1 at 4:59 PM
Esperion Therapeutics, Inc. Fundamental Analysis : November 30, 2017Esperion Therapeutics, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - November 30 at 5:08 PM
Zacks: Brokerages Anticipate Esperion Therapeutics, Inc. (ESPR) to Post -$1.80 Earnings Per ShareZacks: Brokerages Anticipate Esperion Therapeutics, Inc. (ESPR) to Post -$1.80 Earnings Per Share
www.americanbankingnews.com - November 29 at 3:18 PM
Your Daily Pharma Scoop: Regenerons Appeal, Good News For Amgen, Bristol-Myers SprycelYour Daily Pharma Scoop: Regeneron's Appeal, Good News For Amgen, Bristol-Myers' Sprycel
seekingalpha.com - November 13 at 6:56 PM

SEC Filings

Esperion Therapeutics (NASDAQ:ESPR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.